---
title: "Sofinnova-backed Myricx Bio raises GBP 90 million Series A led by Novo Holdings, Abingworth"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292026157.md"
description: "Myricx Bio, a UK oncology company backed by Sofinnova Partners, raised GBP 90 million in a Series A led by Novo Holdings and Abingworth. The funding supports its pivot to an antibody-drug conjugate (ADC) payload platform targeting B7-H3 and HER2 in solid tumors. Notably, Myricx has agreed to be acquired by Novartis for up to USD 1.5 billion, including USD 1.1 billion upfront."
datetime: "2026-07-08T07:07:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292026157.md)
  - [en](https://longbridge.com/en/news/292026157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292026157.md)
---

# Sofinnova-backed Myricx Bio raises GBP 90 million Series A led by Novo Holdings, Abingworth

-   Sofinnova Partners backed Myricx Bio, a UK-origin oncology company developing antibody-drug conjugates using an NMT inhibitor payload platform. \* Sofinnova Partners, Brandon Capital co-led a seed financing in 2019 to test whether the lead molecule could achieve a viable therapeutic index. \* Myricx later raised a GBP 90 million Series A in 2024, with Sofinnova continuing support while remaining the largest investor. \* The financing supported a pivot from a small-molecule program to an ADC payload platform targeting B7-H3 and HER2 in solid tumors. \* Myricx agreed to be acquired by Novartis for up to USD 1.5 billion, including USD 1.1 billion upfront. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sofinnova Partners SAS published the original content used to generate this news brief on July 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [NVS.US](https://longbridge.com/en/quote/NVS.US.md)
- [NOT.DE](https://longbridge.com/en/quote/NOT.DE.md)

## Related News & Research

- [Novartis to buy Myricx Bio for USD 1.1 billion upfront in oncology ADC push](https://longbridge.com/en/news/291755119.md)
- [Novartis CEO shrugs off oral PCSK9 threat amid Q2 growth](https://longbridge.com/en/news/293358257.md)
- [Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway](https://longbridge.com/en/news/293951548.md)
- [Daiichi Sankyo’s Enhertu plus pertuzumab wins EU CHMP backing for first-line HER2+ metastatic breast cancer](https://longbridge.com/en/news/293745706.md)
- [Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestone](https://longbridge.com/en/news/293970382.md)